...
qure-img

Uniqure NV, Common Stock

QURE

NSQ

$17.082

+$0.62

(3.77%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$848.13M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
735.78K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.90
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.73 L
$17.71 H
$17.082

About Uniqure NV, Common Stock

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameQURESectorS&P500
1-Week Return7.58%-3.39%0.2%
1-Month Return166.34%-1.92%2.72%
3-Month Return192.88%-10.54%7.31%
6-Month Return250.96%-4.47%10.44%
1-Year Return106.27%4.06%27.53%
3-Year Return-22.47%0.94%30.88%
5-Year Return-77.13%36.67%89.21%
10-Year Return9.01%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue7.28M37.51M524.00M106.48M15.84M[{"date":"2019-12-31","value":1.39,"profit":true},{"date":"2020-12-31","value":7.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.32,"profit":true},{"date":"2023-12-31","value":3.02,"profit":true}]
Cost of Revenue94.74M122.40M24.98M3.34M13.63M[{"date":"2019-12-31","value":77.4,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.41,"profit":true},{"date":"2022-12-31","value":2.73,"profit":true},{"date":"2023-12-31","value":11.13,"profit":true}]
Gross Profit(87.46M)(84.89M)499.03M103.14M2.21M[{"date":"2019-12-31","value":-17.53,"profit":false},{"date":"2020-12-31","value":-17.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":20.67,"profit":true},{"date":"2023-12-31","value":0.44,"profit":true}]
Gross Margin(1201.15%)(226.28%)95.23%96.86%13.98%[{"date":"2019-12-31","value":-1240.09,"profit":false},{"date":"2020-12-31","value":-233.61,"profit":false},{"date":"2021-12-31","value":98.32,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":14.43,"profit":true}]
Operating Expenses128.42M162.94M188.41M246.30M285.09M[{"date":"2019-12-31","value":45.05,"profit":true},{"date":"2020-12-31","value":57.15,"profit":true},{"date":"2021-12-31","value":66.09,"profit":true},{"date":"2022-12-31","value":86.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(121.14M)(125.43M)310.62M(143.16M)(282.87M)[{"date":"2019-12-31","value":-39,"profit":false},{"date":"2020-12-31","value":-40.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-46.09,"profit":false},{"date":"2023-12-31","value":-91.07,"profit":false}]
Total Non-Operating Income/Expense(3.32M)(18.90M)14.88M3.81M(40.07M)[{"date":"2019-12-31","value":-22.34,"profit":false},{"date":"2020-12-31","value":-127.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.58,"profit":true},{"date":"2023-12-31","value":-269.37,"profit":false}]
Pre-Tax Income(124.20M)(141.44M)332.81M(128.26M)(306.56M)[{"date":"2019-12-31","value":-37.32,"profit":false},{"date":"2020-12-31","value":-42.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.54,"profit":false},{"date":"2023-12-31","value":-92.11,"profit":false}]
Income Taxes3.81M(16.42M)3.22M(1.47M)1.92M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-430.94,"profit":false},{"date":"2021-12-31","value":84.44,"profit":true},{"date":"2022-12-31","value":-38.58,"profit":false},{"date":"2023-12-31","value":50.42,"profit":true}]
Income After Taxes(128.01M)(125.02M)329.59M(126.79M)(308.48M)[{"date":"2019-12-31","value":-38.84,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-93.59,"profit":false}]
Income From Continuous Operations(124.20M)(125.02M)329.59M(126.79M)(228.47M)[{"date":"2019-12-31","value":-37.68,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-69.32,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(128.01M)(125.02M)329.59M(126.79M)(308.48M)[{"date":"2019-12-31","value":-38.84,"profit":false},{"date":"2020-12-31","value":-37.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.47,"profit":false},{"date":"2023-12-31","value":-93.59,"profit":false}]
EPS (Diluted)(3.11)(2.81)6.98(2.71)(6.48)[{"date":"2019-12-31","value":-44.56,"profit":false},{"date":"2020-12-31","value":-40.26,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-38.83,"profit":false},{"date":"2023-12-31","value":-92.84,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

QURE
Cash Ratio 6.11
Current Ratio 6.51
Quick Ratio 6.51

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

QURE
ROA (LTM) -16.62%
ROE (LTM) -147.57%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

QURE
Debt Ratio Lower is generally better. Negative is bad. 0.91
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.09

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

QURE
Trailing PE NM
Forward PE 27.93
P/S (TTM) 29.67
P/B 13.45
Price/FCF NM
EV/R 13.40
EV/Ebitda 0.99
PEG NM

FAQs

What is Uniqure NV share price today?

Uniqure NV (QURE) share price today is $17.082

Can Indians buy Uniqure NV shares?

Yes, Indians can buy shares of Uniqure NV (QURE) on Vested. To buy Uniqure NV from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QURE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Uniqure NV be purchased?

Yes, you can purchase fractional shares of Uniqure NV (QURE) via the Vested app. You can start investing in Uniqure NV (QURE) with a minimum investment of $1.

How to invest in Uniqure NV shares from India?

You can invest in shares of Uniqure NV (QURE) via Vested in three simple steps:

  • Click on Sign Up or Invest in QURE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Uniqure NV shares
What is Uniqure NV 52-week high and low stock price?

The 52-week high price of Uniqure NV (QURE) is $17.71. The 52-week low price of Uniqure NV (QURE) is $3.73.

What is Uniqure NV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Uniqure NV (QURE) is

What is Uniqure NV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Uniqure NV (QURE) is 13.45

What is Uniqure NV dividend yield?

The dividend yield of Uniqure NV (QURE) is 0.00%

What is the Market Cap of Uniqure NV?

The market capitalization of Uniqure NV (QURE) is $848.13M

What is Uniqure NV’s stock symbol?

The stock symbol (or ticker) of Uniqure NV is QURE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top